oxybutynin has been researched along with Age-Related Osteoporosis in 6 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "e risedronate and alendronate in the treatment of osteoporosis." | 7.91 | Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis. ( Cui, P; Jia, B; Kong, F; Wang, D, 2019) |
| "Alendronate (ALD) is clinically indicated for the treatment of osteoporosis, but its therapeutic use has been marred by severe GIT adverse effects affecting quality of life in patients." | 7.88 | Positive effect of alendronate on bone turnover in ovariectomised rats' osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration. ( Boche, M; Pokharkar, V, 2018) |
| "Osteoporosis is a fatal bone-wearing malady and a substantial reason behind the impermanence of human life and economic burden." | 5.91 | Dissolving microneedle transdermal patch loaded with Risedronate sodium and Ursolic acid bipartite nanotransfersomes to combat osteoporosis: Optimization, characterization, in vitro and ex vivo assessment. ( Ali, A; Aqil, M; Jabi, B; Mujeeb, M; Sultana, N; Sultana, Y; Waheed, A; Yaqub Khan, M, 2023) |
| " Nearly six-time enhancement of bioavailability was observed when alendronate was used in the nanoparticulate form in transdermal patches used with sonophoresis." | 5.56 | Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis. ( Huang, G; Li, B; Ma, Z; Qin, S, 2020) |
| " The bioavailability (BA) of alendronate in rats was approximately 8." | 5.36 | Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. ( Abe, M; Hayashi, R; Hirai, Y; Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakai, R; Sakane, T; Ueda, A; Yamamoto, A, 2010) |
| "e risedronate and alendronate in the treatment of osteoporosis." | 3.91 | Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis. ( Cui, P; Jia, B; Kong, F; Wang, D, 2019) |
| "Alendronate (ALD) is clinically indicated for the treatment of osteoporosis, but its therapeutic use has been marred by severe GIT adverse effects affecting quality of life in patients." | 3.88 | Positive effect of alendronate on bone turnover in ovariectomised rats' osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration. ( Boche, M; Pokharkar, V, 2018) |
| "Osteoporosis is a fatal bone-wearing malady and a substantial reason behind the impermanence of human life and economic burden." | 1.91 | Dissolving microneedle transdermal patch loaded with Risedronate sodium and Ursolic acid bipartite nanotransfersomes to combat osteoporosis: Optimization, characterization, in vitro and ex vivo assessment. ( Ali, A; Aqil, M; Jabi, B; Mujeeb, M; Sultana, N; Sultana, Y; Waheed, A; Yaqub Khan, M, 2023) |
| " Nearly six-time enhancement of bioavailability was observed when alendronate was used in the nanoparticulate form in transdermal patches used with sonophoresis." | 1.56 | Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis. ( Huang, G; Li, B; Ma, Z; Qin, S, 2020) |
| " The bioavailability (BA) of alendronate in rats was approximately 8." | 1.36 | Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. ( Abe, M; Hayashi, R; Hirai, Y; Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakai, R; Sakane, T; Ueda, A; Yamamoto, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sultana, N | 1 |
| Ali, A | 1 |
| Waheed, A | 1 |
| Jabi, B | 1 |
| Yaqub Khan, M | 1 |
| Mujeeb, M | 1 |
| Sultana, Y | 1 |
| Aqil, M | 1 |
| Kong, F | 1 |
| Jia, B | 1 |
| Cui, P | 1 |
| Wang, D | 1 |
| Li, B | 1 |
| Huang, G | 1 |
| Ma, Z | 1 |
| Qin, S | 1 |
| Pasqualone, M | 1 |
| Andreetta, HA | 1 |
| Cortizo, MS | 1 |
| Boche, M | 1 |
| Pokharkar, V | 1 |
| Kusamori, K | 1 |
| Katsumi, H | 1 |
| Abe, M | 1 |
| Ueda, A | 1 |
| Sakai, R | 1 |
| Hayashi, R | 1 |
| Hirai, Y | 1 |
| Quan, YS | 1 |
| Kamiyama, F | 1 |
| Sakane, T | 1 |
| Yamamoto, A | 1 |
6 other studies available for oxybutynin and Age-Related Osteoporosis
| Article | Year |
|---|---|
Dissolving microneedle transdermal patch loaded with Risedronate sodium and Ursolic acid bipartite nanotransfersomes to combat osteoporosis: Optimization, characterization, in vitro and ex vivo assessment.
Topics: Drug Delivery Systems; Humans; Osteoporosis; Risedronic Acid; Transdermal Patch; Ursolic Acid | 2023 |
Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium; Drug Delivery Systems; Drug Therapy | 2019 |
Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis.
Topics: Administration, Cutaneous; Alendronate; Animals; Biological Availability; Bone Density Conservation | 2020 |
Risedronate transdermal delivery system based on a fumaric copolymer for therapy of osteoporosis.
Topics: Administration, Cutaneous; Calorimetry, Differential Scanning; Drug Delivery Systems; Humans; Osteop | 2017 |
Positive effect of alendronate on bone turnover in ovariectomised rats' osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration.
Topics: Absorptiometry, Photon; Administration, Cutaneous; Administration, Oral; Alendronate; Animals; Bone | 2018 |
Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Butylated Hydroxytoluene; Calcium; Female; G | 2010 |